Salarius Pharmaceuticals, Inc. (SLRX)
NASDAQ: SLRX · IEX Real-Time Price · USD
0.496
-0.004 (-0.72%)
At close: Apr 15, 2024, 3:36 PM
0.504
+0.008 (1.57%)
After-hours: Apr 15, 2024, 6:18 PM EDT

Salarius Pharmaceuticals Balance Sheet

Millions USD. Fiscal year is Jan - Dec.
Year 202320222021202020192018201720162015
Cash & Equivalents
5.912.1129.2111.123.746.130.5222.5466.81
Short-Term Investments
000000038.6624.65
Cash & Cash Equivalents
5.912.1129.2111.123.746.130.5261.291.47
Cash Growth
-51.27%-58.56%162.75%197.38%-39.02%1080.69%-99.15%-33.09%-
Receivables
01.611.613.86000.020.010
Inventory
00000000.450
Other Current Assets
0.620.8-0.660.820.960.25-0.010.80.78
Total Current Assets
6.5214.5230.1615.84.696.380.5362.4792.25
Property, Plant & Equipment
0000.020.030.040.050.560.38
Long-Term Investments
000000002.31
Goodwill and Intangibles
008.878.878.8700.0700
Other Long-Term Assets
0.070.131.80.250.310.20.040.190.13
Total Long-Term Assets
0.070.1310.679.149.20.230.160.752.82
Total Assets
6.5914.6540.8324.9313.896.610.6963.2195.07
Accounts Payable
0.62.861.541.851.790.380.691.190.88
Deferred Revenue
00000.544.010.960.090
Current Debt
0.29000.480.50000
Other Current Liabilities
0.411.410.570.440.483.50.082.611.97
Total Current Liabilities
1.34.272.112.773.317.881.723.892.85
Other Long-Term Liabilities
00000000.010.03
Total Long-Term Liabilities
00000000.010.03
Total Liabilities
1.34.272.112.773.317.881.723.92.88
Total Debt
0.29000.480.50000
Debt Growth
----5.04%-----
Retained Earnings
-76.35-63.81-32.2-19.43-12.08-5.14-3.47-76.65-37.15
Comprehensive Income
0000000-0-0.02
Shareholders' Equity
5.2910.3838.7222.1610.58-1.27-2.959.3292.19
Net Cash / Debt
5.6112.1129.2110.643.246.130.5261.291.47
Net Cash / Debt Growth
-53.66%-58.56%174.53%228.79%-47.22%1080.69%-99.15%-33.09%-
Net Cash Per Share
1.725.7017.6617.0824.7599.5811.312356.264073.66
Working Capital
5.2210.2528.0513.021.38-1.5-1.1958.5889.4
Book Value Per Share
1.624.8923.4035.5680.93-20.64-63.192283.694106.08
Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).